Niagen Bioscience Inc
NASDAQ:NAGEBiotechnology
Healthcare
$1.94 +3.31%
+$0.11 today
- Market cap
- $153.64M
- Beta
- 2.06
- P/E (TTM)
- 14.9
- EPS (TTM)
- $0.23
52W Low $3.35High $14.69
Volume 0.52M
Average 0.86M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$13.44M
FY 2025 · Annual
+11.0% YoYInvesting Cash Flow
-$292,000.00
FY 2025 · Annual
Financing Cash Flow
$6.98M
FY 2025 · Annual
+30.1% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.13M) | (16.54M) | (4.94M) | 8.55M | 17.38M |
| Depreciation & Amortization | 1.63M | 1.88M | 1.71M | 1.48M | 1.45M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.2M | 5.74M | 4.75M | 3.66M | 6.07M |
| Change in Working Capital | (4.73M) | (6.01M) | 4.62M | 3.13M | (8.3M) |
| Accounts Receivables | (2.58M) | (3.32M) | 2.26M | (1.28M) | (756K) |
| Inventory | (1.92M) | (1.08M) | 152K | 5.33M | (11.64M) |
| Accounts Payables | 978K | (744K) | 553K | (1.07M) | 2.27M |
| Other Working Capital | (1.21M) | (875K) | 1.66M | 147K | 1.83M |
| Other Non-Cash Items | (124K) | (167K) | 977K | (4.72M) | (3.17M) |
| Operating Cash Flow | (24.16M) | (15.1M) | 7.12M | 12.11M | 13.44M |
| Capital Expenditures | (409K) | (334K) | (148K) | (163K) | (292K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 5K | 20K | 0 |
| Investing Cash Flow | (409K) | (334K) | (143K) | (143K) | (292K) |
| Debt Repayment | (31K) | (16K) | (15K) | (11K) | (12K) |
| Common Stock Issued | 26.74M | 7.75M | 0 | 5.43M | 7.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (251K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.39M | (77K) | (75K) | (52K) | 0 |
| Financing Cash Flow | 36.09M | 7.65M | (90K) | 5.37M | 6.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.52M | (7.78M) | 6.88M | 17.34M | 20.13M |
| Free Cash Flow | (24.57M) | (15.43M) | 6.97M | 11.95M | 13.15M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$17.4M
+ D&A$1.4M
+ Stock-Based Comp$6.1M
+ Deferred Tax$0
- Working Capital-$8.3M
- Other Non-Cash-$3.2M
= Operating Cash Flow$13.4M
- Capex-$292.0K
= Free Cash Flow$13.1M
Analysis
FY2025 free cash flow is $13.1M. FCF conversion is 75.6% of net income. Operating cash flow was $13.4M, with capex of -$292.0K. The largest bridge item is Working Capital at -$8.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 |
Does NAGE generate free cash flow?
Niagen Bioscience Inc (NAGE) generated $13.14M of free cash flow in fiscal 2025.
How much operating cash flow does NAGE produce?
Operating cash flow was $13.44M, before capital expenditures of $292,000.00.
Continue the stock analysis
Jump to another research area for this company.